Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.-Reference-Cited by-同舟云学术

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:5509-5509
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Disis Mary L.¹,Patel Manish R.²,Pant Shubham³,Infante Jeffrey R.⁴,Lockhart A. Craig⁵,Kelly Karen⁶,Beck Joseph Thaddeus⁷,Gordon Michael S.⁸,Weiss Glen J.⁹,Ejadi Samuel¹⁰,Taylor Matthew Hiram¹¹,von Heydebreck Anja¹²,Chin Kevin M.¹³,Cuillerot Jean-Marie¹³,Gulley James L.¹⁴

Affiliation:

1. University of Washington School of Medicine, Seattle, WA

2. Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL

3. Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, OK

4. Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

5. Washington University School of Medicine, St. Louis, MO

6. UC Davis Comprehensive Cancer Center, Sacramento, CA

7. Highlands Oncology Group, Rogers, AR

8. Pinnacle Oncology Hematology, Scottsdale, AZ

9. Western Regional Medical Center, Cancer Treatment Centers of America, Goodyear, AZ

10. Virginia G. Piper Cancer Center, Scottsdale, AZ

11. Oregon Health & Science University, Portland, OR